A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521560-36-00

Enrollment

Registered

2026-02-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Brief summary

Recording and reviewing any health problems or side effects that occur during the study, Checking measures of pancreas function related to insulin production

Detailed description

Monitoring blood sugar control, including information from continuous glucose monitoring devices

Interventions

DRUGSAB-142

DRUGSODIUM CHLORIDE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Recording and reviewing any health problems or side effects that occur during the study, Checking measures of pancreas function related to insulin production	—

Secondary

Measure	Time frame
Monitoring blood sugar control, including information from continuous glucose monitoring devices	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026